

L4 ANSWER 4 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
 AN 93001761 EMBASE  
 DN 1993001761  
 TI The treatment of Peyronie's disease with tamoxifen.  
 AU Ralph D.J.; Brooks M.D.; Bottazzo G.F.; Pryor J.P.  
 CS Institute of Urology, Middlesex Hospital, Mortimer Street, London W1 8HH,  
 United Kingdom  
 SO British Journal of Urology, (1992) 70/6 (648-651).  
 ISSN: 0007-1331 CODEN: BJURAN  
 CY United Kingdom  
 DT Journal; Article  
 FS 028 Urology and Nephrology  
 030 Pharmacology  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 LA • English  
 SL English  
 AB This is a preliminary study of the treatment of 36 patients with  
 Peyronie's disease who received tamoxifen 20 mg twice daily for  
 3 months. An improvement occurred in 16 of 20 patients with penile pain,  
 in 11 of 31 patients with an erectile deformity and 12 of 35  
 patients had a plaque shrinkage of at least 1 cm. Some improvement  
 occurred in 6 of the 8 patients with a histologically confirmed  
 inflammatory infiltrate of the plaque but not in any of the 4 patients  
 without an infiltrate. The inflammatory infiltrate was found in patients  
 in whom the duration of the disease was less than 4 months.  
 CT Medical Descriptors:  
 \*pain  
 \*penis  
 \*peyronie disease: DT, drug therapy  
 adult  
 aged  
 article  
 clinical article  
 controlled study  
 hot flush: SI, side effect  
 human  
 libido loss: SI, side effect  
 male  
 oral drug administration  
 priority journal  
 t lymphocyte  
 Drug Descriptors:  
 \*tamoxifen: AE, adverse drug reaction  
 \*tamoxifen: DT, drug therapy  
 \*tamoxifen: DO, drug dose  
 RN (tamoxifen) 10540-29-1